Long Non-Coding Rnas Engender Drug Resistance To Different Subtypes Of Treatments Of Breast Cancers And May Provide A "Next Generation" Therapy Option

The dysfunction of long non-coding RNAs (lncRNAs), without protein-coding potential, has been implicated in drug resistance to treatments in various human diseases, especially in malignant tumors. As the most commonly-diagnosed female malignancy worldwide, breast cancer is also the second-leading cause of cancer-related mortality in women. Despite the improvement in neo-adjuvant therapy, endocrine therapy, molecular-targeted treatment, and chemotherapy, drug resistance to various treatment regimens is still prevalent. This article focused on the lncRNAs and their functions in drug resistance to breast cancer therapeutic agents, in order to develop new precise treatment strategies for patients with breast cancers. The dis- covery of lncRNA opened new doors to the molecular mechanisms of the biological processes, and has provided new pathways to regulate biochemical events. Thus, lncRNAs may be developed as a biomarker for the detection and/or prevention of breast cancer. Additionally, lncRNA-based approaches may provide an additional treatment modality in personalized medicine alone or in combination with existing tumor-directed interventions to improve patient outcomes. In conclusion, lncRNAs molecules may represent the "next generation" therapy option for breast cancer.